EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Chronic myeloid leukemia outcomes according to baseline risk and first‐line treatment in real‐world settings: Data from the Italian Network/CML Campus

Valentina Giai iD, Tiziana Rosso, Fausto Castagnetti, Patrizia Pregno, Massimiliano Bonifacio iD, Isabella Capodanno, Mario Tiribelli iD, Fabio Stagno, Giovanni Caocci, Antonella Gozzini, Luigiana Luciano, Sara Galimberti und 33 weitere

Cancer · 2025

DOI: 10.1002/cncr.35963 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer, 2025. Verfasst von Valentina Giai und 44 weiteren Autor:innen. Beteiligte Einrichtung: Division of Haematology, Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino, Torino, Italy. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Imatinib Mesylate. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Associazione Italiana Leucemia, Linfomi e Mieloma sezione di Bari.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Improved outcome has been reported in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) in sponsored trials.

Methods

This is a multicenter prospective cohort study of consecutive patients with newly diagnosed chronic phase CML from 19 regions in Italy. Baseline treatments and prognostic factors on time to first optimal molecular response (≥ molecular response 3, MR3), time to disease progression, time to death from CML, and overall survival (OS) were analyzed using multivariable Fine and Gray models.

Results

The authors included 1433 CML patients: 49% (median age, 70 years) treated with frontline imatinib (IMA), and 51% treated with second‐generation TKIs (2G‐TKIs; median age, 52 years). EUTOS long‐term survival (ELTS) was low in 68.1% of 2G‐TKIs patients, compared to 50.4% of IMA patients. Faster molecular responses were observed with 2G‐TKIs within the first 6 months and maintained thereafter (subhazard ratio [sHR], 1.31; 95% confidence interval [CI], 1.15–1.50). Female gender and low ELTS risk had faster time of response. Achieving major molecular response (MMR or MR3) was associated with reduced risk of progression at 6 and 12 months. Overall, 41 patients progressed without differences between IMA and 2G‐TKIs. Intermediate and high risk ELTS showed higher risk of progression and death from CML. Twenty‐two CML‐related deaths (16.5%) occurred mostly in the first 2 years from diagnosis, higher in 2G‐TKIs patients (sHR, 1.75; 95% CI, 0.52–5.87). OS at 5 years was 88% with no clear differences between IMA and 2G‐TKIs treatment after adjustment for potential confounders.

Conclusions

The study confirms faster responses with 2G‐TKIs compared to IMA but similar clinical outcomes and a strong prognostic effect of ELTS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveImatinib MesylateHumansMaleFemaleMiddle AgedAgedItalyAdultProspective StudiesTreatment OutcomeAged, 80 and overPrognosisDisease Progression

Stichwörter der Autor:innen

TKIchronic myeloid leukemiafirst‐line treatmentimatinibreal‐life studyrisk factorssecond generation TKI

Substanzen

Protein Kinase InhibitorsImatinib Mesylate

Autor:innen und Institutionen

  • Division of Haematology, Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino, Torino, Italy.
  • Clinical Epidemiology Unit and CPO Piemonte, Città della Salute e della Scienza di Torino, Torino, Italy.
  • Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Institute of Hematology "L. & A. Seràgnoli", Bologna, Italy.
  • Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
  • Hematology, AUSL Reggio Emilia, Reggio Emilia, Italy.
  • Division of Hematology and BMT, Azienda Ospedaliero-Universitaria di Udine, Udine, Italy.

ORCID-Profile: Valentina Giai, Massimiliano Bonifacio, Mario Tiribelli, Nicola Di Renzo, Massimo Breccia

Förderung

  • Associazione Italiana Leucemia, Linfomi e Mieloma sezione di Bari

Zitieren

APA

Giai, V., Rosso, T., Castagnetti, F., Pregno, P., Bonifacio, M., Capodanno, I., Tiribelli, M., Stagno, F., Caocci, G., Gozzini, A., Luciano, L., Galimberti, S., Bocchia, M., Patriarca, A., Lanzarone, G., Martino, B., Guella, A., Scortechini, A. R., Fava, C., …, & Breccia, M. (2025). Chronic myeloid leukemia outcomes according to baseline risk and first‐line treatment in real‐world settings: Data from the Italian Network/CML Campus. Cancer. https://doi.org/10.1002/cncr.35963

Vancouver

Giai V, Rosso T, Castagnetti F, Pregno P, Bonifacio M, Capodanno I, et al. Chronic myeloid leukemia outcomes according to baseline risk and first‐line treatment in real‐world settings: Data from the Italian Network/CML Campus. Cancer. 2025. doi:10.1002/cncr.35963

BibTeX
@article{Giai2025,
  author = {Giai, Valentina and Rosso, Tiziana and Castagnetti, Fausto and Pregno, Patrizia and Bonifacio, Massimiliano and Capodanno, Isabella and Tiribelli, Mario and Stagno, Fabio and Caocci, Giovanni and Gozzini, Antonella and Luciano, Luigiana and Galimberti, Sara and Bocchia, Monica and Patriarca, Andrea and Lanzarone, Giuseppe and Martino, Bruno and Guella, Anna and Scortechini, Anna Rita and Fava, Carmen and Fozza, Claudio and Sica, Simona and Di Renzo, Nicola and Musto, Pellegrino and Pastore, Domenico and Maggi, Alessandro and Pizzuti, Michele and Melillo, Lorella Maria Antonia and Carella, Angelo Michele and Tarantini, Giuseppe and Mele, Anna and Calistri, Elisabetta and Coppi, Maria Rosaria and Saccona, Fabio and Scalzulli, Emilia and Battaglio, Beatrice and Iezza, Miriam and Bitetti, Cinzia and Freilone, Roberto and Rosti, Gianantonio and Albano, Francesco and Pane, Fabrizio and Specchia, Giorgina and Ciccone, Giovannino and Saglio, Giuseppe and Breccia, Massimo},
  title = {Chronic myeloid leukemia outcomes according to baseline risk and first‐line treatment in real‐world settings: Data from the Italian Network/CML Campus},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35963}
}
Kostenlos starten →